96-31253. Roger Pharmacy; Revocation of Registration  

  • [Federal Register Volume 61, Number 238 (Tuesday, December 10, 1996)]
    [Notices]
    [Pages 65079-65081]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 96-31253]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF JUSTICE
    [Docket No. 95-4]
    
    
    Roger Pharmacy; Revocation of Registration
    
        On October 7, 1994, the Deputy Assistant Administrator. Office of 
    Diversion Control, Drug Enforcement Administration (DEA), issued an 
    Order to show Cause to Roger Pharmacy (Respondent) of Gahanna, Ohio, 
    notifying the pharmacy of an opportunity to show cause as to why DEA 
    should not revoke its DEA Certificate of Registration, BR1448655, and 
    deny any pending applications for renewal of such registration as a 
    retail pharmacy under 21 U.S.C. 823(f), for reason that the pharmacy's 
    continued registration would be inconsistent with the public interest 
    pursuant to 21 U.S.C. 824(a)(4).
        On November 2, 1994, the Respondent, through counsel, filed a 
    timely request for a hearing, and following prehearing procedures, a 
    hearing was held in Cleveland, Ohio on June 27, 1995, before 
    Administrative Law Judge Mary Ellen Bittner. At the hearing, both 
    parties called witnesses to testify, and the Government introduced 
    documentary evidence. After the hearing, counsel for both parties 
    submitted proposed findings of fact, conclusions of law and argument. 
    On April 9, 1996, Judge Bittner issued her Opinion and Recommended 
    Ruling, Findings of Fact, Conclusions of Law and Decision, recommending 
    that Respondent's DEA Certificate of Registration be revoked. Neither 
    party filed exceptions to her decision, and on May 10, 1996, Judge 
    Bittner transmitted the record of these proceedings to the Deputy 
    Administrator.
        The Acting Deputy Administrator has considered the record in its 
    entirety, and pursuant to 21 CFR 1316.67, hereby issues his final order 
    based upon findings of fact and conclusions of law as hereinafter set 
    forth. The Acting Deputy Administrator adopts, in full, the Findings of 
    Fact, Conclusions of Law, and Recommended Ruling of the Administrative 
    Law Judge, and his adoption is in no manner diminished by any 
    recitation of facts, issues and conclusions herein, or of any failure 
    to mention a matter of fact or law.
        The Acting Deputy Administrator finds that Jon R. Martin, R.Ph. 
    purchased Respondent pharmacy, located in Gahanna Ohio, in the late 
    1980's. Respondent is a high volume drug store that employees 10 to 15 
    individuals, and provides services not generally available from chain 
    pharmacies, such as charge accounts and deliveries to the elderly.
        In November 1990, a detective with the Narcotics Bureau of the 
    Columbus, Ohio Police Department conducted a routine inspection of 
    Respondent pharmacy and its exempt narcotics log book. Under both 
    Federal and state law a prescription is not required to purchase 
    certain Schedule V cough syrups, however a log book must be maintain 
    containing the name and address of the purchaser, the name and quantity 
    of the controlled substance purchased, the date of purchase, and the 
    name of the dispensing pharmacist. In addition, there is a limit on the 
    amount of cough syrup that may be purchased by an individual within a 
    48 hour period. The inspection revealed that on 11 occasions, between 
    February 1989 and November 1990, individuals had purchased Schedule V 
    exempt narcotic cough syrups from Respondent more than once in a 48 
    hour period in violation of both Federal and state law. Further 
    examination of Respondent's exempt narcotic log book revealed that 
    certain individuals bought exempt narcotics from Respondent frequently 
    and over an extended period of time. Specifically, between February 20, 
    1989 and November 18, 1990, an individual purchased exempt narcotics 
    from Respondent on 126 occasions; between March 24, 1989 and February 
    7, 1990, an individual purchased exempt narcotics from Respondent on 63 
    occasions; another individual purchased exempt narcotics from 
    Respondent on 97 occasions between January 2, 1989 and February 3, 
    1991; between January 15, 1989 and December 29, 1990, an individual 
    purchased exempt narcotics from Respondent on 104 occasion; an 
    individual purchased exempt narcotics on 87 occasions between January 
    16, 1989 and February 10, 1991; and another individual purchased exempt 
    narcotics from Respondent on 34 occasions between August 25, 1990 and 
    February 2, 1991.
        The detective interviewed three of these individuals who all 
    admitted purchasing exempt narcotics from Respondent. One stated that 
    when he went to Respondent, there would be a bottle of cough syrup 
    waiting for him by the time he reached the pharmacy counter. Another 
    individual admitted to signing the log book using different names.
        On January 30, 1991, the detective interviewed Jon Martin, 
    Respondent's owner and pharmacist, and asked him how long it would take 
    someone to become addicted to codeine if he/she drank a bottle of cough 
    syrup every day or every other day. Mr. Martin stated that in his 
    opinion it would take approximately 60 days. The detective then asked 
    Mr. Martin why he continued to sell cough syrup to the same 
    individuals. Mr. Martin replied that as long as customers stayed within 
    the 48 hour rule, he would sell the cough syrup to them because if he 
    did not, they would just buy it elsewhere. Mr. Martin went on to state 
    that the pharmacy business is a tough business and he might as well 
    make money.
        In April 1991, the Columbus Police Department informed DEA of the 
    results of its investigation of Respondent. DEA compared the amount of 
    exempt narcotics sold by Respondent with the amount sold by the other 
    five pharmacies located in Gahanna, Ohio, and discovered that during an 
    average month in 1991, Respondent sold twice the quantity of exempt 
    narcotic products as all the other local pharmacies combined. On April 
    18, 1991, DEA went to Respondent pharmacy to evaluate its compliance 
    with the Controlled Substances Act. It was discovered that Respondent 
    did not have a biennial inventory as required by Federal regulations. 
    At the hearing before Judge Bittner, when asked about this Respondent 
    stated that, ``I suspect it was just a matter of being a little lax on 
    getting things done. It was nothing intentional. There's a lot of 
    things for me to do. * * * Some of them are nit-picky things I 
    neglected doing. I'm sorry.'' The DEA investigators also discovered 
    that Respondent could not account for 18 of the 126 Schedule II order 
    forms that it had been issued by DEA between January 1989 and April 
    1991. Respondent testified at the hearing before Judge Bittner that he 
    was surprised that the order forms were missing, and that ``paperwork 
    has not always been one of (his) strong suits.''
        As part of its investigation, DEA conducted an accountability audit 
    at Respondent pharmacy of eight controlled substances. The audit 
    revealed both overages and shortages of all but one of the audited 
    substances. For example, Respondent pharmacy could account for 164 
    tablets of Dilaudid 2 mg. (a Schedule II controlled substances) more 
    than it was accountable, and could not account for 1,160 tablets of 
    APAP with codeine (a Schedule III controlled substance) for
    
    [[Page 65080]]
    
    which it was accountable. At the hearing before Judge Bittner, Mr. 
    Martin stated that had he been informed of the shortages at the time of 
    the investigation, he probably could have accounted for the shortages. 
    However, both the DEA investigator that testified at the hearing and 
    Mr. Martin testified that at the time of the accountability audit, the 
    investigator asked Mr. Martin several times if he had given or shown 
    the investigator all of the pharmacy's controlled substances and 
    records.
        The DEA investigator returned to Respondent pharmacy on April 25, 
    1991, to verify refill information, and discovered that Respondent's 
    records did not indicate dates of refills or verification by the 
    dispensing pharmacist. The investigator also discovered that 
    Respondent's records of oral prescriptions did not include information 
    required by Federal regulations. The investigator seized seven 
    controlled substance prescriptions issued to an individualy purportedly 
    by one doctor. On April 30, 1991, the investigator met with the doctor 
    who advised the investigator that he had not authorized one of the 
    prescriptions at all and that another prescription that he had issued 
    had been refilled five times, when he had only authorized one refill.
        As a result of the investigation by the Columbus Police Department, 
    the Ohio State Board of Pharmacy (Board) found that on nine occasions 
    between March 1989 and November 1990, Mr. Martin had violated the 48 
    hour rule regarding the dispensing of exempt narcotics, and that he had 
    sold codeine cough syrup for other than a legitimate medical purpose. 
    The Board concluded that Mr. Martin was guilty of gross immorality, 
    dishonesty and unprofessional conduct in the practice of pharmacy, and 
    on August 11, 1992, suspended his license to practice pharmacy for one 
    year, fined him $5,000.00, but permitted the pharmacy to continue 
    operating without restriction.
        Mr. Martin pled guilty in the United States District Court for the 
    Southern District of Ohio to one misdemeanor count of unlawful 
    distribution of a codeine-based exempt narcotic, and in September 1993, 
    he was placed on probation for one year, fined $2,500.00 and ordered to 
    perform 50 hours of community service. Mr. Martin paid the fine, but 
    was excused from performing some of the community service, and his 
    probation was terminated early.
        Both the Columbus detective and the DEA investigator testified at 
    the hearing in this matter that they have not received any complaints 
    regarding Respondent's controlled substance dispensing since the 
    investigation in 1991. Mr. Martin testified at the hearing that he 
    assumes full responsibility for what happened at Respondent pharmacy, 
    and that he has instituted procedural changes so nothing like it will 
    happen again. The pharmacy no longer sells exempt narcotics without a 
    prescription even though a prescription is not required by Federal or 
    state law. Mr. Martin has hired a pharmacist to be responsible for all 
    controlled substance inventories, Schedule II order forms, and other 
    DEA requirements. It is now the pharmacy's policy to call prescribing 
    doctors to verify refill information, and to note that information on 
    the prescription and in the computer.
        However, Mr. Martin admitted at the hearing that he was aware that 
    certain individuals came to his pharmacy to buy Schedule V cough syrup 
    because he always sold it to them. When asked why the pharmacy stopped 
    selling exempt narcotics without a prescription, Mr. Martin testified, 
    ``it's cost me a lot of money and a lot of time and a lot of anguish in 
    my life that I really don't need. And besides that, I certainly wasn't 
    helping the people.''
        Pursuant to 21 U.S.C. 823(f) and 824(a)(4), the Deputy 
    Administrator may revoke a DEA Certificate of Registration and deny any 
    pending applications, if he determines that the continued registration 
    would be inconsistent with the public interest. Section 823(f) requires 
    that the following factors be considered:
        (1) The recommendation of the appropriate State licensing board or 
    professional disciplinary authority.
        (2) The applicant's experience in dispensing, or conducting 
    research with respect to controlled substances.
        (3) The applicant's conviction record under Federal or State laws 
    relating to the manufacture, distribution, or dispensing of controlled 
    substances.
        (4) Compliance with applicable State, Federal, or local laws 
    relating to controlled substances.
        (5) Such other conduct which may threaten the public health and 
    safety.
    These factors are to be considered in the disjunctive; the Deputy 
    Administrator may rely on any one or a combination of factors and may 
    give each factor the weight he deems appropriate in determining whether 
    a registration should be revoked or an application for registration be 
    denied. See Henry J. Schwarz, Jr., M.D., Docket No. 88-42, 54 FR 16,422 
    (1989). In this case, factors one, two, three and four are relevant in 
    determining the public interest.
        As to factor one, ``recommendation of the appropriate licensing 
    board * * *'' in 1992, the Ohio State Board of Pharmacy found that Mr. 
    Martin had dispensed coedine cough syrup for no legitimate medical 
    purpose and in violation of the prohibition against dispensing more 
    than once in a 48 hour period to the same individual. As a result, the 
    Board suspended Mr. Martin's license to practice pharmacy for one year. 
    Mr. Martin's license to practice pharmacy and Respondent's license are 
    currently unrestricted. While it is relevant that Respondent and its 
    owner possess unrestricted state authorization to handle controlled 
    substances, the Acting Deputy Administrator does not find it 
    dispositive of whether Respondent's continued registration is in the 
    public interest.
        As to factor two, the Respondent's ``experience in dispensing * * * 
    controlled substances,'' the Acting Deputy Administrator concurs with 
    the Administrative Law Judge that ``this factor strongly weighs in 
    favor of finding that Respondent's registration would not be in the 
    public interest.'' In the case of Schedule V exempt narcotic cough 
    syrups dispensed without a prescription, the responsibility to ensure 
    that these substances are dispensed for a legitimate medical purpose 
    rests solely with the pharmacist. See Arthur Sklar, R.Ph., d/b/a/ King 
    Pharmacy, 54 FR 34,623 (1989). The Ohio State Board of Pharmacy found 
    that Mr. Martin dispensed exempt narcotics to certain individuals for 
    no legitimate medical purpose. Mr. Martin admitted that he was aware 
    that certain individuals came to his pharmacy to buy Schedule V cough 
    syrup for no legitimate medical purpose, because he always sold it to 
    them. He stated that if he didn't sell it to them, they'd just go buy 
    it elsewhere. He violated the prohibitions against dispensing exempt 
    narcotics to the same individual more than once in a 48 hour period. It 
    was Mr. Martin's opinion that an individual who took Schedule V cough 
    syrup every day or every other day, could become addicted within 60 
    days, yet he continued to dispense these substances to individuals on a 
    regular basis over several years. The Acting Deputy Administrator 
    agrees with Judge Bittner's finding that ``Mr. Martin abrogated his 
    professional and legal responsibilities with respect to dispensing 
    controlled substances.''
        Regarding factor three, it is uncontested that in September 1993, 
    Mr. Martin pled guilty in the United States District Court for the 
    Southern District of Ohio to one misdemeanor count of unlawful 
    distribution of a codeine-based exempt narcotic, and he
    
    [[Page 65081]]
    
    was placed on probation for one year, fined $2,500.00 and ordered to 
    perform 50 hours of community service.
        As to factor four, the Respondent's ``[c]ompliance with applicable 
    State, Federal, or local laws relating to controlled substances,'' the 
    evidence presented at the hearing in this matter clearly supports the 
    conclusion that Respondent committed numerous violations of applicable 
    laws and regulations. Respondent failed to maintain complete and 
    accurate records of its controlled substances as required by 21 U.S.C. 
    827 and 21 CFR 1304.21, as evidenced by the results of the 
    accountability audit. Respondent failed to conduct a biennial inventory 
    of its controlled substances as required by 21 CFR 1304.13. Pursuant to 
    21 CFR 1305.13, Respondent was required to preserve all Schedule II 
    order forms. Its inability to account for 18 of its order forms 
    indicates a violation of this regulation.
        Respondent's maintenance of records regarding oral prescriptions 
    and prescriptions refills was also deficient. Under 21 CFR 1306.21, a 
    pharmacist may dispense a Schedule III or IV controlled substance 
    pursuant to an oral prescription that is promptly reduced to writing by 
    the pharmacist. The writing must contain all of the information 
    required for a written prescription, including the date of issuance, 
    the name and address of patient, and the name, address, and 
    registration number of the prescribing practitioner. Respondent's oral 
    prescription information failed to include the name and address of both 
    the patient and the practitioner. Respondent's prescription refill 
    records failed to include the date of the refill or verification 
    information by the dispensing pharmacist, in violation of 21 CFR 
    1306.22(b) (1) and (3).
        Respondent violated Section 3719.16 of the Ohio Revised Code and 21 
    CFR 1306.32 by selling codeine cough syrup on 11 occasions to the same 
    individual more than once within a 48 hour period.
        Of considerable concern to the Acting Deputy Administrator is 
    Respondent's violation of 21 CFR 1306.04(a), which provides that:
    
        A prescription for a controlled substance to be effective must 
    be issued for a legitimate medical purpose by an individual 
    practitioner acting in the usual course of his professional 
    practice. The responsibility for the proper prescribing and 
    dispensing of controlled substances is upon the prescribing 
    practitioner, but a corresponding responsibility rests with the 
    pharmacist who fills the prescription * * *
    
    Accordingly, in situations where a prescription for a controlled 
    substance is issued, both the prescribing practitioner and the 
    dispensing pharmacist have the responsibility to ensure that the 
    substances are being dispensed for a legitimate medical purpose. In 
    this case, however, there is no prescribing practitioner. Therefore, 
    the dispensing pharmacist bears the sole responsibility for evaluating 
    the purpose and necessity for the dispensing of controlled substances. 
    Mr. Martin himself admits that he ignored his responsibilities and 
    dispensed the Schedule V cough syrups for no legitimate medical 
    purpose. He attempted to justify his behavior by stating that if he did 
    not sell the cough syrup, the customers would just go elsewhere. His 
    only concern was to make money. Based upon these numerous violations of 
    Federal and state laws and regulations relating to the dispensing of 
    controlled substances, factor four is extremely significant in 
    evaluating the public interest in this case.
        Like Judge Bittner, the Acting Deputy Administrator notes Mr. 
    Martin's testimony regarding the procedural changes that he has 
    instituted to ensure that Respondent would comply with applicable laws 
    and regulations in the future. However, he has delegated most of the 
    responsibility concerning compliance to a pharmacist at Respondent. As 
    the owner of Respondent, Mr. Martin is ultimately responsible for 
    compliance, and by his own admission, he has not spent much time at 
    Respondent recently.
        The Acting Deputy Administrator concludes that regardless of 
    whether Mr. Martin is present at the pharmacy or not, Respondent's 
    continued registration is inconsistent with the public interest. Judge 
    Bittner found that ``Mr. Martin displayed a total disregard for federal 
    and State laws and regulations, and for his responsibilities as a 
    licensed pharmacist and owner of a DEA registrant.'' The Acting Deputy 
    administrator concurs with Judge Bittner's assertion that ``Mr. Martin 
    testified that he accepted responsibility for his misconduct and 
    recognized that he used poor judgment; however, his expression of 
    regret was directed more to the consequences to himself of his action--
    the aggravation and loss of time and money--than to the conduct 
    itself.'' Mr. Martin turned a blind eye to his duty as a DEA registrant 
    to ensure that controlled substances were dispensed for a legitimate 
    medical purpose. He characterized many of the registration requirements 
    as ``nit-picky things.'' Those requirements are in place to guard 
    against the diversion of controlled substances. To minimize these 
    requirements demonstrates a lack of appreciation for the 
    responsibilities of a DEA registrant. Consequently, the Acting Deputy 
    administrator concludes that Respondent's continued registration is 
    inconsistent with the public interest.
        Accordingly, the Acting Deputy Administrator of the Drug 
    Enforcement Administration, pursuant to the authority vested in him by 
    21 U.S.C. 823 and 824 and 28 CFR 0.100(b) and 0.104, hereby orders that 
    DEA Certificate of Registration BR1448655, issued to Roger Pharmacy, 
    be, and it hereby is revoked and any pending applications for renewal 
    of such registration, be, and they hereby are, denied. This order is 
    effective January 9, 1997.
    
        Dated: December 2, 1996.
    James S. Milford,
    Acting Deputy Administrator.
    [FR Doc. 96-31253 Filed 12-9-96; 8:45 am]
    BILLING CODE 4410-09-M
    
    
    

Document Information

Published:
12/10/1996
Department:
Justice Department
Entry Type:
Notice
Document Number:
96-31253
Pages:
65079-65081 (3 pages)
Docket Numbers:
Docket No. 95-4
PDF File:
96-31253.pdf